Sinovac's CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
28 December 2009 - 11:00PM
PR Newswire (US)
BEIJING, Dec. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.
(NASDAQ:SVA), a leading provider of biopharmaceutical products in
China, announced today that Weidong Yin, Chairman, President &
CEO, was presented with the Annual Innovation Award by China
Central Television (CCTV). As previously announced, Mr. Yin had
been one of 18 nominees for the CCTV's China's 2009 Economic
Man-of-the-Year. Results were announced on December 23, 2009 at an
award ceremony held in Beijing. Mr. Weidong Yin was honored because
of his contribution to the battle against the H1N1 influenza
pandemic; Sinovac vaccines protect human life and strengthen the
Chinese people's confidence. Mr. Weidong Yin, Chairman, President
and CEO of Sinovac, remarked, "I am very pleased to have received
CCTV's 2009 Annual Innovation Award. As the first company worldwide
to receive approval for the H1N1 vaccine, we have exemplified
Sinovac's position as a true innovator in the global vaccine
industry. We are proud that our entire portfolio of innovative
vaccines continues to make a significant contribution to the health
and well-being of Chinese citizens." Recipients of the Top Ten 2009
Economic Man-of-the-Year award were CEO and president of Sina
Charles Chao, China Minsheng Banking Corporation Chairman Dong
Wenbiao, Shenzhen Capital Group Chairman Jin Haitao, chairman of
Geely Automobile Holding Li Shufu, Guangdong Galanz Enterprise
Group CEO Liang Chao-Hsien, chairman of Jiangsu Shagang Group Shen
Wenrong, chairman and CEO at Neusoft Group Ltd Liu Jiren, Phoenix
Publishing & Media Group chairman Tan Yue, Chongqing Changan
Automobile Co., Ltd., chairman Xu Liuping, and chairman of New
Oriental Education Group Yu Minhong. In addition, Liu Haitao, head
of Shanghai Institute of Microsystem and Information Technology
under the Chinese Academy of Sciences, received the Annual
Innovation Award. About Sinovac Sinovac Biotech Ltd. is a
China-based biopharmaceutical company that focuses on the research,
development, manufacture and commercialization of vaccines that
protect against human infectious diseases. Sinovac's vaccine
products include Healive(R) (hepatitis A), Bilive(R) (combined
hepatitis A and B), and Anflu(R) (influenza). Panflu(R) and
PANFLU.1(TM), Sinovac's pandemic influenza vaccine (H5N1) and H1N1
vaccine, have already been approved for government stockpiling.
Sinovac is developing vaccines for enterovirus 71, universal
pandemic influenza, Japanese encephalitis, and human rabies. Its
wholly owned subsidiary, Tangshan Yian, is conducting field trials
for independently developed inactivated animal rabies vaccine. Safe
Harbor Statement This announcement contains forward-looking
statements. These statements are made under the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These forward-looking statements can be identified by words
or phrases such as "will," "expects," "anticipates," "future,"
"intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from
management in this press release contain forward-looking
statements. Statements that are not historical facts, including
statements about Sinovac's beliefs and expectations, are
forward-looking statements. Forward-looking statements involve
inherent risks and uncertainties. A number of important factors
could cause actual results to differ materially from those
contained in any forward- looking statement. Sinovac does not
undertake any obligation to update any forward-looking statement,
except as required under applicable law. For more information,
please contact: Helen G. Yang Sinovac Biotech Ltd. Tel:
+86-10-8289-0088 x9871 Fax: +86-10-6296-6910 Email: Investors: Amy
Glynn/Stephanie Carrington The Ruth Group Tel: +1-646-536-7023/7017
Email: Media: Janine McCargo The Ruth Group Tel: +1-646-536-7033
Email: DATASOURCE: Sinovac Biotech Ltd. CONTACT: Helen G. Yang of
Sinovac Biotech Ltd., +86-10-8289-0088 x9871, fax +86-10-6296-6910,
; or Investors, Amy Glynn, +1-646-536-7023, , or Stephanie
Carrington, +1-646-536-7017, , or Media, Janine McCargo,
+1-646-536-7033, , all of The Ruth Group, for Sinovac Biotech Ltd.
Copyright